Are you busy during this broadcast? See Broadcast #2 for an alternative time.
In immuno-oncology, companion diagnostics are used in conjunction with targeted drugs and therapies to identify patients who are likely to benefit from a specific treatment regimen or who may have increased risk for certain side effects. Join this webinar for a discussion of the integration of digital pathology, clinical trial design and tissue-based testing solutions for biomarker validation to quickly advance immuno-oncology therapies to pivotal clinical trial-scale studies.
Florian Leiss, Director Profiling & Diagnostics, Definiens
Florian Leiss heads Definiens’ business for tissue profiling and diagnostics. His professional background includes business development, corporate strategy, product management, and marketing communications. He studied Biochemistry (Technical University Munich) and holds PhDs in Neuroscience (Max Planck Institute for Neuroscience, Munich) and Philosophy (Ludwigs-Maximilians-University, Munich).Message Presenter
Who Should Attend?
- Translational Scientists
- VP Oncology
- Directors of Immuno-Oncology Programs
- Directors of Companion Diagnostics
- Directors of Profiling
- Clinical Trial Managers/Directors/VP
What You Will Learn
Join this webinar to learn about:
- Strategies to accelerate immuno-oncology drug and diagnostic co-development
- Integrating multiplex immunohistochemistry, in situ hybridization and -omics data in early-stage clinical programs
- Utilizing digital pathology, machine learning and deep learning to create unique patient phenotypic profiles that support individualized diagnostic and therapy decisions
We improve patient lives by unlocking the tissue phenome.
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Definiens’ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.